<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1661-6146</issn>
      <issn pub-type="ppub">1661-6138</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">08892</article-id>
      <article-id pub-id-type="doi">10.4414/fms.2022.08892</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Der besondere Fall</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Allergologie / Immunologie</subject>
          <subject>Klinische Pharmakologie und Toxikologie</subject>
          <subject>Medizinische Onkologie</subject>
          <subject>Neurologie</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Encéphalite paranéoplasique liée à un «checkpoint ­inhibitor»</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Mattsson</surname>
            <given-names>Kevin</given-names>
          </name>
          <email>kevin.mattsson@rhne.ch</email>
          <aff>Médecine interne | Chasseral 20 | Chaux-de-Fonds | 2300 | SWITZERLAND | +41795829123</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Zender</surname>
            <given-names>Hervé O.</given-names>
          </name>
          <email>herve.zender@rhne.ch</email>
          <aff>Service de médecine interne,
Département de médecine,
Réseau hospitalier neuchâtelois</aff>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Olivier</surname>
            <given-names>Philippe</given-names>
          </name>
          <email>philippe.olivier@rhne.ch</email>
          <aff>Service de neurologie,
Département de médecine,
Réseau hospitalier neuchâtelois</aff>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="pub" iso-8601-date="2022.05.24">
        <day>24</day>
        <month>05</month>
        <year>2022</year>
      </pub-date>
      <volume>22</volume>
      <issue>2122</issue>
      <fpage>365</fpage>
      <lpage>368</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2022</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="fr">
        <p>Les récentes immunothérapies en oncologie mettent en lumière des résultats jamais obtenus auparavant en termes de survie en lien avec une néoplasie métastatique. Les complications possibles de ces nouveaux traitements sont par contre multiples et présentent de nombreux diagnostics différentiels. Nous relatons par cet article une brève revue des complications neurologiques en lien avec les immunothérapies, illustrée par le cas d'un patient présentant une encéphalite para-néoplasique à anticorps anti-Hu dans le contexte d'une immunothérapie par checkpoint inhibitor (atezolizumab). Nous illustrons également la complexité de la prise en charge de telles pathologiques.</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
